Summit Securities Group LLC Sells 5,438 Shares of Merck & Co., Inc. $MRK

Summit Securities Group LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 66.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,800 shares of the company’s stock after selling 5,438 shares during the quarter. Summit Securities Group LLC’s holdings in Merck & Co., Inc. were worth $360,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of MRK. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $25,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter worth $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the fourth quarter valued at about $26,000. High Note Wealth LLC raised its holdings in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $31,000. 76.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares of the company’s stock, valued at $4,942,755. This represents a 21.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 228,238 shares of company stock worth $29,977,783. Insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MRK. Wells Fargo & Company upped their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Bank of America boosted their price target on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. UBS Group increased their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday. Finally, Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $142.10.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their individualized mRNA vaccine, used with Merck’s Keytruda, met the Phase 3 primary endpoint in high-risk melanoma. The combination improved recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, marking the first positive late-stage result for an mRNA cancer vaccine. The result could expand Merck’s oncology pipeline and help address the eventual loss of Keytruda exclusivity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: Morgan Stanley upgraded MRK to overweight and raised its price target to $179 from $116, while UBS lifted its target to $175 and BMO raised its target to $170, reflecting increased confidence in the cancer-vaccine opportunity and Merck’s broader growth prospects. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Neutral Sentiment: Analysts cautioned that the initial results are not a complete regulatory or commercial victory. Full data, regulatory approval expected no earlier than 2027, manufacturing execution and the therapy’s eventual pricing and market adoption remain key uncertainties. Moderna’s Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
• Negative Sentiment: RBC downgraded MRK to sector perform and set a $150 target, arguing that the roughly $150 valuation is unusually demanding for a company facing a major Keytruda loss of exclusivity in about two years. Jefferies also moved the stock to hold, creating a valuation overhang despite the trial success. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Broader healthcare weakness and profit-taking after Merck’s sharp rally are adding pressure, while the stock’s elevated valuation leaves less room for disappointment. Sector Update: Healthcare Stocks Fall Thursday Afternoon

Merck & Co., Inc. Stock Down 1.9%

MRK opened at $149.25 on Friday. The company has a market capitalization of $368.23 billion, a PE ratio of 119.40, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19. The firm has a 50-day simple moving average of $127.43 and a two-hundred day simple moving average of $121.01. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $153.50.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business’s revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.